PharmiNews

The Directory of Pharma Companies and News

MGB Biopharma

MGB Biopharma logo
MGB Biopharma is developing a truly novel class of anti-infectives. Its lead candidate, MGB-BP-3, is an antibacterial which is active against a broad range of important multi-resistant Gram-positive pathogens. The Company has developed an oral formulation of MGB-BP-3 for the treatment of Clostridium difficile that is ready to enter the clinic, whilst an intravenous formulation targeting the treatment of a range of systemic hospital acquired Gram-positive infections is in late-stage preclinical development. MGB Biopharma has close links with the University of Strathclyde, with exclusive worldwide licence rights to the University's MGB patents for all fields except anti-cancer. The Company intends to work with partners to fully capitalise on the multiple value creating opportunities offered by its broad and novel anti-infectives platform. The Company was founded in 2010 and is headquartered in Glasgow, Scotland. It is backed by Scottish investors including Archangel Investors, Barwell, TRI Cap and the Scottish Investment Bank, Scottish Enterprise.
Category: Biotech
Category: Biotech

MGB Biopharma News

DateNews
2016-09-12MGB Biopharma Granted Qualified Infectious Disease Product (QIPD) Designation by U.S. FDA for the Treatment of Clostridi...
2016-06-14MGB Biopharma to Present Poster at Upcoming ASM Microbe Meeting in Boston on 20 June 2016
2016-05-19MGB Biopharma Welcomes Jim O’Neill’s Final Recommendations for the World to Defeat Superbugs
2016-05-09MGB Biopharma’s Pre-IND Meeting with FDA Provides Clear Guidelines on Further Development of Oral MGB-BP-3, a Truly Nove...
2016-02-16MGB Biopharma and University of Strathclyde Sign New Agreement to Develop Novel MGB Anti-Infectives to Tackle a Key Mech...
2015-12-09MGB Biopharma successfully completes Phase I clinical trial with Oral MGB-BP-3 – a truly novel antibiotic targeting Clos...
2015-11-17MGB Biopharma Successfully Completes Feasibility Study with Topical Formulation of its Lead Antibacterial MGB-BP-3
2015-10-29MGB Biopharma to attend BIO-Europe 2015
2015-09-10MGB Biopharma Wins Scottish Business Award
2015-07-21MGB Biopharma commences Phase I clinical trial with oral formulation of MGB-BP-3 for the treatment of multi-resistant Cl...
2015-06-02MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resista...
2015-05-15MGB Biopharma Fully Supports the Latest Report from Jim O’Neill’s Review on Antimicrobial Resistance
2015-03-24MGB Biopharma to Present at the Superbugs & Superdrugs Conference in London on 26th March
2015-01-12MGB Biopharma continues to progress its truly novel anti-infectives platform to tackle antibiotic resistance in 2014
2014-12-08MGB Biopharma Announces Collaborations with Almac Group Ltd and Encap Drug Delivery to Manufacture Lead Antibiotic MGB-B...
2014-12-01MGB Biopharma Nominated and Shortlisted for Scottish Enterprise Life Sciences Award
2014-11-26MGB Biopharma in the News – European Pharmaceutical Contractor
2014-09-17MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development
2014-08-26MGB Biopharma In the News – MedNous
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.